In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on Keros Therapeutics (KROS – Research Report), with a price target of $26.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tiago Fauth’s rating is based on Keros Therapeutics’ strategic initiatives to enhance shareholder value and optimize company operations. The decision to return $375 million in excess capital to shareholders is seen as a positive move, reflecting the company’s commitment to financial prudence and potentially boosting investor confidence. This capital return follows a strategic review and is supported by a substantial cash reserve, which stood at $720.5 million as of the end of March 2025.
Additionally, Keros Therapeutics has taken steps to streamline its operations, including a recent headcount reduction aimed at achieving significant annual savings. While the company’s clinical asset ‘065 shows promise with encouraging data, expectations remain cautious due to its early development stage. Despite mixed short-term sentiment, the stock is trading below its cash value, suggesting potential upside as the company progresses with its strategic plans.
Fauth covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, United Therapeutics, and Savara. According to TipRanks, Fauth has an average return of 0.4% and a 43.50% success rate on recommended stocks.
In another report released on May 30, Scotiabank also maintained a Buy rating on the stock with a $26.00 price target.